Posted by Michael Wonder on 19 Nov 2025
FDA approves selumetinib for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas
19 November 2025 - Today, the FDA approved selumetinib (Koselugo, AstraZeneca Pharmaceuticals) for adults with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.
The FDA previously approved selumetinib capsules and granules for paediatric patients 1 year of age and older for this indication.
